[ad_1]
Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.
Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion
Leave a comment
Your Trusted Source for Accurate and Timely Updates!
Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
